According to DelveInsight's analysis, the current developmental pipeline for osteoarthritis is robust, with several companies initiating clinical trials to investigate new treatment options or improve ...

In 2013, two years after leaving Pfizer, Kindler became CEO of Centrexion Therapeutics, a Boston-based company focused on using non-opioid products to ease chronic pain. Kindler still holds the ...

In a challenging year for Centrexion Therapeutics Corp, the biopharmaceutical company’s stock has tumbled to a 52-week low, touching down at $0.55. Despite the current market pressure, InvestingPro ...

Centrexion Therapeutics stock hits 52-week low at $0.55 View all comments (0) 0 Latest comments Post Comment Guidelines Trade With A Regulated Broker Indices Commodities Bonds Stocks US 30 42,045. ...

Google’s new ‘G’ logo appeared on stage during the I/O 2025 keynote, and is now live in more apps and the web. The new logo made its debut with the Google app on Android and iOS last week.

The updated "G" logo has a gradient effect now, which could be an attempt to better sync design with the company's AI products. Imad is a senior reporter covering Google and internet culture.

CRISPR Therapeutics won its first regulatory approval a little over a year ago, and has compelling candidates in the pipeline. Of course, Vertex's success didn't happen overnight -- and the ...

Building a climate-controlled warehouse and logistics facility for United Therapeutics in North Carolina’s Research Triangle was a matter of power management and careful planning. The facility ...

Centrexion Therapeutics Corp hits 52-week high, reaching 2.285 USD Open in App ...

Centrexion Therapeutics Corp (CNTX) has reached a new 52-week high, with its share price soaring to 2.285 USD. This milestone reflects a significant upward trend for the biopharmaceutical ...

Emerging therapeutic insights spotlight Centrexion Therapeutics' lead drug candidate, CNTX-4975, possibly revolutionizing the treatment landscape for osteoarthritis in major markets across the globe.